New England Asset Management Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 37,100 shares of the company’s stock after buying an additional 3,350 shares during the period. New England Asset Management Inc.’s holdings in Eli Lilly and were worth $3,120,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Private Capital Advisors Inc. boosted its position in Eli Lilly and by 9.7% in the first quarter. Private Capital Advisors Inc. now owns 384,564 shares of the company’s stock worth $32,346,000 after buying an additional 34,141 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Eli Lilly and by 3.5% in the first quarter. Bank of Montreal Can now owns 904,360 shares of the company’s stock valued at $76,066,000 after buying an additional 30,775 shares in the last quarter. Gradient Investments LLC boosted its position in shares of Eli Lilly and by 8.3% in the first quarter. Gradient Investments LLC now owns 85,342 shares of the company’s stock valued at $7,178,000 after buying an additional 6,523 shares in the last quarter. CrestPoint Capital Management LLC boosted its position in shares of Eli Lilly and by 320.7% in the first quarter. CrestPoint Capital Management LLC now owns 12,200 shares of the company’s stock valued at $1,026,000 after buying an additional 9,300 shares in the last quarter. Finally, Beutel Goodman & Co Ltd. bought a new position in shares of Eli Lilly and during the first quarter valued at about $161,084,000. Hedge funds and other institutional investors own 75.61% of the company’s stock.

Shares of Eli Lilly and Company (NYSE LLY) traded down 0.47% on Friday, hitting $81.15. 2,446,392 shares of the stock traded hands. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock’s 50 day moving average price is $82.91 and its 200 day moving average price is $81.72. The stock has a market cap of $85.61 billion, a P/E ratio of 35.11 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the previous year, the firm earned $0.86 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.

COPYRIGHT VIOLATION NOTICE: “New England Asset Management Inc. Has $3.12 Million Position in Eli Lilly and Company (LLY)” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/12/new-england-asset-management-inc-has-3-12-million-position-in-eli-lilly-and-company-lly.html.

LLY has been the topic of several research analyst reports. BMO Capital Markets cut shares of Eli Lilly and from a “market perform” rating to an “underperform” rating and reduced their price target for the company from $73.00 to $71.00 in a research report on Monday, April 17th. Morgan Stanley cut shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price target on the stock. in a research report on Monday, April 17th. Cowen and Company boosted their price target on shares of Eli Lilly and from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday, April 17th. Piper Jaffray Companies reiterated a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research report on Monday, April 17th. Finally, Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Tuesday, April 18th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $88.27.

In other news, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the transaction, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 669,733 shares of company stock worth $55,845,287. Insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.